ROAR trial: which treatment is effective after progression?

Affiliations

¹ Department of Medical Oncology, Gazi University, Ankara 06560, Turkey. Electronic address: sutcuogluo@gmail.com.
² Department of Medical Oncology, Gazi University, Ankara 06560, Turkey.

Comment

Osman Sütcüoğlu et al. Lancet Oncol. 2022 Mar.

. 2022 Mar;23(3):e93.

doi: 10.1016/S1470-2045(21)00754-3.

¹ Department of Medical Oncology, Gazi University, Ankara 06560, Turkey. Electronic address: sutcuogluo@gmail.com.
² Department of Medical Oncology, Gazi University, Ankara 06560, Turkey.

No abstract available

Conflict of interest statement

We declare no competing interests.

ROAR trial: which treatment is effective after progression? - Authors' reply.
Wen PY, Burgess P, Ilankumaran P, Subbiah V. Wen PY, et al. Lancet Oncol. 2022 Mar;23(3):e94. doi: 10.1016/S1470-2045(22)00076-6. Lancet Oncol. 2022. PMID: 35240095 No abstract available.

Dabrafenib plus trametinib in patients with BRAF^V600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, von Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A, Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah V. Wen PY, et al. Lancet Oncol. 2022 Jan;23(1):53-64. doi: 10.1016/S1470-2045(21)00578-7. Epub 2021 Nov 24. Lancet Oncol. 2022. PMID: 34838156 Clinical Trial.